Shumin Ouyang

962 total citations · 1 hit paper
19 papers, 640 citations indexed

About

Shumin Ouyang is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Shumin Ouyang has authored 19 papers receiving a total of 640 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Molecular Biology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Shumin Ouyang's work include Cytokine Signaling Pathways and Interactions (6 papers), Cancer Mechanisms and Therapy (5 papers) and RNA modifications and cancer (3 papers). Shumin Ouyang is often cited by papers focused on Cytokine Signaling Pathways and Interactions (6 papers), Cancer Mechanisms and Therapy (5 papers) and RNA modifications and cancer (3 papers). Shumin Ouyang collaborates with scholars based in China, Macao and United States. Shumin Ouyang's co-authors include Xiaolei Zhang, Yuanxiang Wang, Jianshan Mo, Peibin Yue, Peiqing Liu, Jiaye Lu, Ziyou Lin, Kai Zhu, Linlin Lou and Huaxuan Li and has published in prestigious journals such as Cancer Research, Journal of Medicinal Chemistry and Fuel.

In The Last Decade

Shumin Ouyang

17 papers receiving 634 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer

2022 323 citations Shumin Ouyang, Huaxuan Li et al. Redox Biology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shumin Ouyang China	9	378	253	229	178	88	19	640
Hongjing Zang China	17	536 1.4×	188 0.7×	242 1.1×	223 1.3×	79 0.9×	42	769
Jianshan Mo China	7	271 0.7×	228 0.9×	179 0.8×	150 0.8×	50 0.6×	15	477
Jiaye Lu China	8	306 0.8×	224 0.9×	205 0.9×	116 0.7×	99 1.1×	15	556
Nicolaos Palaskas United States	8	625 1.7×	316 1.2×	290 1.3×	266 1.5×	143 1.6×	10	898
Daniela Frezzetti Italy	13	358 0.9×	110 0.4×	266 1.2×	175 1.0×	59 0.7×	18	613
Lin Zhong China	9	304 0.8×	221 0.9×	220 1.0×	111 0.6×	43 0.5×	21	523
Conghua Lu China	13	295 0.8×	181 0.7×	96 0.4×	190 1.1×	60 0.7×	39	528
Lais Osmani United States	5	305 0.8×	261 1.0×	192 0.8×	238 1.3×	69 0.8×	10	613
Liming Gui China	9	322 0.9×	238 0.9×	202 0.9×	114 0.6×	102 1.2×	15	553
Kang‐Lai Wei China	13	441 1.2×	148 0.6×	325 1.4×	202 1.1×	64 0.7×	27	680

Countries citing papers authored by Shumin Ouyang

Since Specialization

Citations

This map shows the geographic impact of Shumin Ouyang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shumin Ouyang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shumin Ouyang more than expected).

Fields of papers citing papers by Shumin Ouyang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shumin Ouyang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shumin Ouyang. The network helps show where Shumin Ouyang may publish in the future.

Co-authorship network of co-authors of Shumin Ouyang

This figure shows the co-authorship network connecting the top 25 collaborators of Shumin Ouyang. A scholar is included among the top collaborators of Shumin Ouyang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shumin Ouyang. Shumin Ouyang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Zhang, Rui, Qingzhi Zhang, Liangfu Zhou, et al.. (2025). Trio-amine blends combined with fly ash-catalyzed desorption: A synergistic approach for energy-efficient CO2 capture. Fuel. 404. 136311–136311.

Ouyang, Shumin, Ziyou Lin, Mei Lü, et al.. (2025). The IGF2BP3–FASN axis drives lipid metabolic reprogramming to promote brain colonization in non-small cell lung cancer. Cell Death and Disease. 16(1). 684–684.

Wang, Pengyan, Wen Ding, Jianshan Mo, et al.. (2025). A novel adenosine 2A receptor antagonist HZ-086 enhances the efficiency of immunotherapy and alleviates the acquired resistance to PD-L1 by restoration of T cell functions. European Journal of Pharmacology. 997. 177535–177535. 1 indexed citations

Ding, Wen, Jianzheng Zhu, Jianshan Mo, et al.. (2025). Neuropeptide Precursor VGF Promotes Neuroendocrine Differentiation and Cancer-Associated Fibroblast Activation in Small Cell Lung Cancer. Cancer Research. 85(22). 4469–4484. 2 indexed citations

Lou, Linlin, Shumin Ouyang, Jianshan Mo, et al.. (2025). Periostin-mediated NOTCH1 activation between tumor cells and HSCs crosstalk promotes liver metastasis of small cell lung cancer. Journal of Experimental & Clinical Cancer Research. 44(1). 6–6. 1 indexed citations

Zhang, Qiyi, Wen Ding, Jianshan Mo, et al.. (2024). Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma. Acta Pharmacologica Sinica. 45(8). 1701–1714. 8 indexed citations

Ouyang, Shumin, Shuo Shi, Ge Yang, et al.. (2024). Neuropeptide Precursor VGF Promotes Liver Metastatic Colonization of Gαq Mutant Uveal Melanoma by Facilitating Tumor Microenvironment via Paracrine Loops. Advanced Science. 11(46). e2407967–e2407967. 3 indexed citations

Lin, Ziyou, Jian Zhang, Weineng Feng, et al.. (2023). Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non–Small Cell Lung Cancer. Cancer Research. 83(13). 2187–2207. 75 indexed citations

Lu, Jiaye, Jingwei Li, Ziyou Lin, et al.. (2023). Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer. Cancer Letters. 564. 216205–216205. 57 indexed citations

10.

Ouyang, Shumin, Qiyi Zhang, Linlin Lou, et al.. (2022). The Double-Edged Sword of SIRT3 in Cancer and Its Therapeutic Applications. Frontiers in Pharmacology. 13. 871560–871560. 23 indexed citations

11.

Li, Huaxuan, Shumin Ouyang, Yi Zhang, et al.. (2022). Structural optimization of Imidazo[1, 2-a]pyridine derivatives for the treatment of gastric cancer via STAT3 signaling pathway. European Journal of Medicinal Chemistry. 244. 114858–114858. 6 indexed citations

12.

Yang, Ge, Junjie Deng, Jianzheng Zhu, et al.. (2022). Discovery of small molecule Gαq/11 protein inhibitors against uveal melanoma. Acta Pharmaceutica Sinica B. 12(8). 3326–3340. 13 indexed citations

13.

Deng, Linhong, Jianshan Mo, Yi Zhang, et al.. (2022). Boronic Acid: A Novel Pharmacophore Targeting Src Homology 2 (SH2) Domain of STAT3. Journal of Medicinal Chemistry. 65(19). 13094–13111. 9 indexed citations

14.

Ouyang, Shumin, Huaxuan Li, Linlin Lou, et al.. (2022). Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer. Redox Biology. 52. 102317–102317. 323 indexed citations breakdown →

15.

Chen, Lihua, et al.. (2022). Connexin 37 Regulates the Kv1.3 Pathway and Promotes the Development of Atherosclerosis. Mediators of Inflammation. 2022. 1–9. 7 indexed citations

16.

Zhong, Yan, Linhong Deng, Shuo Shi, et al.. (2021). The novel STAT3 inhibitor WZ-2-033 causes regression of human triple-negative breast cancer and gastric cancer xenografts. Acta Pharmacologica Sinica. 43(4). 1013–1023. 27 indexed citations

17.

Zhong, Yan, Bingbing Li, Shumin Ouyang, et al.. (2021). Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3). European Journal of Medicinal Chemistry. 221. 113525–113525. 9 indexed citations

18.

Liang, Shuang, Weiwei Mu, Zipeng Zhang, et al.. (2021). Amphiphilic small molecular mates match hydrophobic drugs to form nanoassemblies based on drug-mate strategy. Asian Journal of Pharmaceutical Sciences. 17(1). 129–138. 8 indexed citations

19.

Dong, Hui, Jianshan Mo, Yi Zhang, et al.. (2020). A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance. Theranostics. 11(2). 824–840. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact